JP2023512843A - 移植後不整脈を治療および予防する方法 - Google Patents

移植後不整脈を治療および予防する方法 Download PDF

Info

Publication number
JP2023512843A
JP2023512843A JP2022548412A JP2022548412A JP2023512843A JP 2023512843 A JP2023512843 A JP 2023512843A JP 2022548412 A JP2022548412 A JP 2022548412A JP 2022548412 A JP2022548412 A JP 2022548412A JP 2023512843 A JP2023512843 A JP 2023512843A
Authority
JP
Japan
Prior art keywords
administration
amiodarone
ivabradine
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512843A5 (https=
Inventor
ビョルン ノルマン
ロバート スコット ティース
ウィリアム ロブ マクレラン
ケンタ ナカムラ
チャールズ イー． マリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2023512843A publication Critical patent/JP2023512843A/ja
Publication of JP2023512843A5 publication Critical patent/JP2023512843A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022548412A 2020-02-10 2021-02-09 移植後不整脈を治療および予防する方法 Pending JP2023512843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972330P 2020-02-10 2020-02-10
US62/972,330 2020-02-10
PCT/US2021/017220 WO2021163037A1 (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Publications (2)

Publication Number Publication Date
JP2023512843A true JP2023512843A (ja) 2023-03-29
JP2023512843A5 JP2023512843A5 (https=) 2024-07-02

Family

ID=77291628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548412A Pending JP2023512843A (ja) 2020-02-10 2021-02-09 移植後不整脈を治療および予防する方法

Country Status (11)

Country Link
US (1) US20230077983A1 (https=)
EP (1) EP4103206A4 (https=)
JP (1) JP2023512843A (https=)
KR (1) KR20220140532A (https=)
CN (1) CN115484966A (https=)
AU (1) AU2021218653A1 (https=)
BR (1) BR112022015768A2 (https=)
CA (1) CA3166678A1 (https=)
IL (1) IL295236A (https=)
MX (1) MX2022009807A (https=)
WO (1) WO2021163037A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025010384A (ja) * 2019-06-06 2025-01-20 ノヴォ ノルディスク アー／エス 幹細胞由来心筋細胞への抗不整脈剤の適用およびその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230250393A1 (en) * 2022-02-09 2023-08-10 University Of Washington Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
WO2023173123A1 (en) * 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
EP4593821A2 (en) * 2022-09-28 2025-08-06 Bluerock Therapeutics LP Compositions and methods for treating graft-related arrhythmia
WO2025137525A1 (en) * 2023-12-22 2025-06-26 Bluerock Therapeutics Lp Molecular identification of cardiomyocytes for cardiac cell therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140363841A1 (en) * 2012-01-20 2014-12-11 Singapore Health Services Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof
JP2022535435A (ja) * 2019-06-06 2022-08-08 ノヴォ ノルディスク アー／エス 幹細胞由来心筋細胞への抗不整脈剤の適用およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994812B2 (en) * 2012-04-04 2018-06-12 University Of Washington Through Its Center For Commercialization Systems and method for engineering muscle tissue
US9855317B2 (en) * 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
AU2018235964A1 (en) * 2017-03-15 2019-08-15 Cambridge Enterprise Limited Methods and compositions for enhancing cardiomyocyte maturation and engraftment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140363841A1 (en) * 2012-01-20 2014-12-11 Singapore Health Services Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof
JP2022535435A (ja) * 2019-06-06 2022-08-08 ノヴォ ノルディスク アー／エス 幹細胞由来心筋細胞への抗不整脈剤の適用およびその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, vol. 119, JPN6025002364, 2009, pages 1814 - 1823, ISSN: 0005511132 *
CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, vol. 18(10), JPN6025002362, 2016, pages 61, ISSN: 0005511133 *
HEART RHYTHM, vol. 13, no. 6, JPN6025002365, 2016, pages 1297 - 1302, ISSN: 0005644181 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025010384A (ja) * 2019-06-06 2025-01-20 ノヴォ ノルディスク アー／エス 幹細胞由来心筋細胞への抗不整脈剤の適用およびその使用

Also Published As

Publication number Publication date
IL295236A (en) 2022-10-01
MX2022009807A (es) 2022-11-10
AU2021218653A1 (en) 2022-09-01
EP4103206A4 (en) 2024-03-13
CN115484966A (zh) 2022-12-16
US20230077983A1 (en) 2023-03-16
KR20220140532A (ko) 2022-10-18
BR112022015768A2 (pt) 2022-11-22
WO2021163037A1 (en) 2021-08-19
EP4103206A1 (en) 2022-12-21
CA3166678A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP2023512843A (ja) 移植後不整脈を治療および予防する方法
Tedesco et al. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells
JP7333271B2 (ja) 心筋細胞の成熟および生着を増強するための方法および組成物
JP7715781B2 (ja) 進行性心不全の予防
CN107257687B (zh) 用于治疗心力衰竭的方法
Yuko et al. LIN28a induced metabolic and redox regulation promotes cardiac cell survival in the heart after ischemic injury
US20240226178A1 (en) Electrophysiological modification to suppress arrhythmias
Wang et al. Reconstitute the damaged heart via the dual reparative roles of pericardial adipose-derived flk-1+ stem cells
US8889122B2 (en) Cellular cardiomyoplasty as supportive therapy in patients with heart disease
US20230250393A1 (en) Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
KR102051221B1 (ko) Cfc 신드롬 환자의 발달 저해를 완화 할 수 있는 치료용 조성물
EP4722346A1 (en) Cardiomyocyte group, pharmaceutical composition, method for producing cardiomyocyte group, and myocardial sphere
Villanueva Glyoxalase 1 attenuates the effects of chronic hyperglycemia on explant-derived cardiac stem cells
du Pré Circadian Rhythms in Cardiovascular Disease. From Bench to Bedside
Tchao Engineered human cardiac tissue from muscle derived stem cells
KR101694063B1 (ko) Ｂｉｏ 화합물을 함유하는 심혈관질환의 치료용 조성물
Noiseux et al. STEM CELLS THERAPY FOR ISCHEMIC CARDIOVASCULAR DISEASES: NEW INSIGHTS ON MECHANISMS AND FATE OF THE IMPLANTED CELLS
Noiseux et al. Autologous Stem Cells for Cardiac Repair: New Insights on Clinical Trial Safety and Best Cell Source
Castaldi Pharmacological activation and reprogramming of muscle cells to acquire an earlier, pluripotent, circulating" stem-like" behaviour, suitable for therapeutical applications
Wolfram et al. Is the Therapeutic Potential of Stem Cells for Myocardial Regeneration Limited by Proarrhythmic Effects?
Sherin Age-dependent variation in stem cell characteristics of the healthy and diseased heart
Bekkers et al. Myocardial regeneration via intracardiac stem cells Marie-José Goumans, and Pieter A Doevendans
Bekkers et al. Myocardial Regeneration via Intracardiac Stem Cells
Hughey Characterizing the Relationship Between Energy Metabolism and Mesenchymal Stem Cell Therapy in the Infarcted Heart

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250717